FDA continues its run of indication-first approvals with Aimmune’s peanut allergy therapy

FDA’s approval of Aimmune’s peanut allergy therapy continues the momentum of what’s expected to be a big year for approvals in indications with no available treatment options.

The agency approved Palforzia Friday to reduce the incidence and severity of allergic reactions following accidental peanut exposure in patients aged 4-17 after an FDA advisory panel voted 7-2 in

Read the full 569 word article

How to gain access

Continue reading with a
two-week free trial.